BIOTECHNOLOGY

Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain.

The Callisto™ Sample Prep System offers programmable, precise, and plastic-free liquid manipulation with pre-optimized applications to support short- and long-read sequencing workflows. With a growing menu of library prep kits powered by Watchmaker Genomics' solutions, Volta Labs will continue to expand the universe of pre-optimized applications available through Callisto and enable labs to maximize advancements in sequencing.

The new HiFi library prep kits are expected to be available for purchase in the first quarter of 2024, with delivery planned early in the second quarter of 2024. Automated protocols will first be available on the Hamilton NGS STAR system, with qualified protocols on additional PacBio Compatible automation platform partners being added in the future. Kits contain enough volume for customers to develop their own automated methods notes PacBio.

The collaboration aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).

BIOTRONIK notes Over the past decades, more than 20 clinical studies that enrolled over 4,000 patients have confirmed the safety and efficacy of DX Technology. This strong foundation of clinical evidence has recently been enriched by the MATRIX study results, the largest clinical evaluation of DX Technology to date. Results from the MATRIX study confirm under real-world conditions that DX, with Home Monitoring, allows for reliable, guideline-recommended remote monitoring of subclinical AF.

AtlasXomics and EpiCypher have focused initial development efforts on fresh frozen samples. Their long-term goal is to optimize spatial CUT&Tag for formalin-fixed paraffin-embedded (FFPE) samples, thereby greatly enhancing the versatility of these assays for clinical applications.